BioCentury | Jun 23, 2020
Distillery Therapeutics

Blocking cGAS signaling for alcohol-related liver disease

DISEASE CATEGORY: Hepatic INDICATION: Liver disease Targeting the cGAS-IRF3 signaling pathway by inhibiting cGAS or the gap junction protein GJB1 could treat alcohol-related liver disease. In liver samples from alcoholic-related liver disease patients, high cGAS...
BioCentury | Jul 18, 2019
Financial News

Kronos parlays diverse pipeline into $105M series A

The speed at which Kronos assembled a broad small molecule platform against hard-to-target hormone receptors, transcription factors and E3 ligases enabled it to raise a $105 million A round led by seed investors Vida Ventures...
BioCentury | Dec 14, 2018
Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) reported Phase II data from a cohort of eight evaluable newly diagnosed, biomarker-positive acute myelogenous leukemia (AML) patients showing that tamibarotene (SY-1425) plus Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG) led to...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

INDICATION: Renal cancer Patient sample and mouse studies suggest promoting expression of IRF9 and STAT2 could help treat clear cell renal cell carcinoma (ccRCC). In patients, low levels of IRF9 in tumor samples were associated...
BioCentury | Aug 30, 2018
Translation in Brief

Turning off the inflammasome

In a July Nature paper , a team from the University of California San Diego identified CMPK2 as a potential target for inflammatory diseases involving NLRP3 inflammasomes and may launch a spinout to develop the findings....
BioCentury | Apr 12, 2018
Translation in Brief

Viral variant vaccine

A team from Duke-NUS Medical School rapidly developed a live-attenuated Zika vaccine candidate by exploiting genetic errors to identify a strain with high viremia and reduced propagation. The approach could speed development of live vaccines...
BioCentury | Apr 10, 2018
Preclinical News

Researchers identify coding, non-coding driver mutations in MM

Scientists from the Institute of Cancer Research (London, U.K.) identified coding and non-coding driver mutations involved in newly diagnosed multiple myeloma, suggesting the genes could be targeted to treat the disease. The research was published...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample, cell culture and mouse studies suggest inhibiting IRF3 could help treat gastric cancer. In patient samples, high levels of IRF3 tumor RNA and protein correlated with tumor size and poor...
BioCentury | Jan 18, 2018
Preclinical News

Chromosomal instability can trigger metastasis via STING activity

A paper published in Nature brings into question the safety and efficacy of activating the transmembrane protein 173 (STING; TMEM173) pathway -- which triggers immune responses in the presence of cytosolic DNA -- in cancers...
BioCentury | Jan 4, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS,...
Items per page:
1 - 10 of 43